Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

273.91 +7.32 (+2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
The Latest Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals
Via Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Via Benzinga
Lululemon Athletica To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
Needham raised the price target for F5, Inc. (NASDAQ: FFIV) from $175 to $180. Needham analyst Alex Henderson maintained a Buy rating. F5 shares jumped 11.2% to $167.00 in pre-market trading. 
Via Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Shares of BridgeBio Pharma Skyrocketed This Week
The biotech company saw strong results in a phase 3 trial. 
Via The Motley Fool
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Alnylam Pharmaceuticals Topped the Market Today
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder. 
Via The Motley Fool
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and  
Via Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
The companies are working on treatments for a leading cause of heart failure. 
Via Investor's Business Daily
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals
Via Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by 
Via Benzinga
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for... 
Via Benzinga
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.